

CANCER EDUCATION DAY

Post Radiotherapy Angiosarcoma

Dr. Vikas Garg

June 13, 2025

Presenter Disclosure

- None

Epidemiology and risk factors



Low Incidence Rate

Radiation-associated sarcomas account for only 3-6% of all sarcomas.
Absolute risk is under 1% in exposed populations (0.09-0.14%).
Higher for breast sarcoma/angiosarcoma (0.4-0.8 %).



Common Primary Cancers

Most cases occur after breast cancer, lymphoma, head and neck, and gynecologic cancers.




Extended Latency Period

Risk persists 20-30 years after treatment.
Typical onset is 5-10 years post-radiation.




Risk Increases With Dose

Higher radiation doses correlate with increased risk, though can occur with doses below 40 Gy.
Others: age at radiation therapy and duration from primary treatment, exposure to chemotherapy.



Pathophysiology



- Radiation must be sufficient to cause genetic damage but not cell death.
- MYC gene amplification is present in over 80% of radiation-induced angiosarcoma cases.
- High p53 signature

Clinical features

Skin Manifestations


Ecchymotic macular or purplish papular lesions

- Often multiple lesions
- Can present with skin edema (peau d'orange)

Common Symptoms

Progressive, painless mass in radiation field

- Some report pain or compression symptoms
- Paresthesias or edema in extremities



Breast/Chest Wall

Common location after breast cancer treatment

- Primarily affects skin rather than parenchyma
- Often multifocal

Rectal/ gynecologic

Bleeding in rectal/gynecological

Radiologic diagnosis

MRI Imaging (Preferred)

Better delineation of soft tissue structures

Distinguish a radiation-associated sarcoma from a recurrence

CT Imaging

Useful for defining tumor size and local extent.

CT chest to detect pulmonary metastases

Mammography

May show trabecular thickening and skin changes separate from original breast cancer site.

Enhancing cutaneous nodules.



Pathology



Biopsy Planning

Multidisciplinary approach involving surgeon, radiologist, and pathologist. Complete staging studies before biopsy.



Histologic Examination

Shows irregular vascular channels lined by abnormal endothelial cells. Often high-grade with increased mitotic activity.




Immunohistochemistry

Positive for vascular markers: CD31 (gold standard), Factor-VIII, CD34, and VEGF.



Genetic Testing

MYC gene amplification present in majority of radiation-associated angiosarcomas. High p53 signatures.



Prognosis

10-50%

5-Year Survival Rate

Lower than primary sarcomas

40-50%

Post-Resection Survival

When complete resection is achieved

50-65%

Local Recurrence Rate

Despite curative intent surgery

25-44%

Distant Recurrence Rate

Common sites: lung, liver, bone marrow

- Prognosis worse for angiosarcoma compared to other sarcomas, secondary angiosarcoma have worse prognosis compared to primary



Management



Surgical Resection

Mastectomy required for breast angiosarcomas



Reirradiation

Careful consideration in previously irradiated field



Systemic Therapy

Chemotherapy for high risk, metastatic or unresectable disease

Surgery

Discussion in multidisciplinary team at a sarcoma center has shown improved outcomes

High rate of local recurrence with breast conservative surgery

5 yr disease-specific survival for radical versus conservative resections was 86 and 46 percent, respectively

Radical mastectomy with extensive resection and removal of previously irradiated skin with margin of 3 cm

May requires a skin graft or myocutaneous flap.

For clinically negative axilla, sentinel lymph node biopsy or axillary lymph node dissection is not routinely indicated

Radiation



Role of adjuvant RT is unclear



High rate of late effects of a high cumulative RT dose (rib fracture, pneumonitis, soft tissue necrosis)



High rate of disease recurrence with surgery alone (50 to 73 percent)



Reirradiation with a hyperfractionated schedule shown favorable results

Chemotherapy

Lack of prospective data, studies with mixed histology

No clear benefit, ? disease-free survival/local control

Individualized decision after thorough discussion

Reasonable for tumour >3-5 cm, node positive, very close or positive margins

Taxane preferred especially in patients who previously received prior anthracycline

Metastatic disease



Treatment with palliative intent in most cases



Patient with isolated pulmonary metastasis may be considered for metastasectomy



Chemotherapy responses short lived,



Taxane based chemotherapy most effective



Others doxorubicin, liposomal doxorubicin, ifosfamide.



Other therapies:

Tyrosine kinase inhibitors
Immunotherapy
Beta adrenergic blockers

[BMC Cancer 2018; 18: 963](#)
[Cancer Manag Res 2018; 10: 1089-1114](#)
[J Immunother Cancer 2019; 7:213](#)

Conclusion

Post RT angiosarcoma is rare complication of breast radiation

Aggressive disease with tendency for local/distant recurrence and unusual sites of metastasis

Local disease treated with extensive surgery

Metastatic disease treated with palliative intent with chemotherapy, taxanes preferred

Question & Answer